Clinical Trial Update: Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide

View source ↗

Summary

The study completed evaluation of PSA level changes in patients with advanced prostate cancer treated with bicalutamide.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• bicalutamide (bicalutamide)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Prostate Cancer | Status: COMPLETED